<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346914</url>
  </required_header>
  <id_info>
    <org_study_id>NTL-LEES-2019-03</org_study_id>
    <nct_id>NCT04346914</nct_id>
  </id_info>
  <brief_title>Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer</brief_title>
  <official_title>Phase Ib Study of Recombinant Anti-PD-L1 Monoclonal Antibody Injection (ZKAB001) Combined With Carboplatin and Etoposide in the Treatment of Extensive Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection
      (ZKAB001) combined with carboplatin and etoposide in the treatment of extensive-stage small
      cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and preliminary efficacy of recombinant anti-PD-L1（Programmed cell
      death ligand 1）monoclonal antibody injection (ZKAB001) combined with carboplatin and
      etoposide in the treatment of extensive-stage small cell lung cancer. The study will last
      until the number of patients who permanently stop taking drugs due to toxicity in the first
      two cycles is less than 1/3 of the total number of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>28 days after first dose</time_frame>
    <description>The number of patients who permanently stop taking drugs due to toxicity is less than 1/3 of the total number of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of patients in partial and complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>time between first dose of study drug to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The positive rate of PD-L1 expression in tumor tissue</measure>
    <time_frame>12 months</time_frame>
    <description>The positive rate of PD-L1 expression in tumor tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The positive rate of anti-drug antibody (ADA);</measure>
    <time_frame>12 months</time_frame>
    <description>The positive rate of anti-drug antibody (ADA);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>time between first dose of study drug to death caused by any reason</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Extensive Stage Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Combined treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide</intervention_name>
    <description>ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1~3，q3w</description>
    <arm_group_label>Combined treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  both men and women, age ≥ 18 years old and ≤ 75 years old.

          -  histologically confirmed SCLC

          -  extensive stage SCLC (ES-SCLC) according to (VALG) staging of American Veterans Lung
             Cancer Association.

          -  have not received first-line systemic therapy for ES-SCLC in the past.

          -  surgery and adjuvant therapy for cure, such as radiotherapy and chemotherapy, were
             performed in the past, and there was no treatment interval of at least 6 months from
             the last chemotherapy, radiotherapy or radiotherapy or chemotherapy to the diagnosis
             of ES-SCLC.

          -  PS 0 or 1.

          -  estimated survival time &gt; 12 weeks.

          -  CT or MRI scan with at least one measurable lesion less than 28 days before the first
             dose of the study drug (RECIST v1.1).

          -  male subjects and women of childbearing age must have contraception within 6 months
             from the beginning of the first drug study to the last study drug.

          -  before the first dose of the drug, the laboratory test values met the following
             conditions: (1) Blood routine test: WBC ≥ 3.0x10^9 / L, ANC ≥ 1.5x10^9 /L, PLT ≥
             100x10^9 /L, hGB ≥ 90g / L; (2) liver function: AST ≤ 2.5 ULN, ALT ≤ 2.5 ULN; ALT and
             AST &lt; 5 ULN for liver metastases; TBIL ≤ 1.5 ULN; ALB ≥ 30 g L; (3) Renal function:
             serum creatinine ≤ 1.5 ULN or creatinine clearance rate (Ccr) ≥ 40 mL/min
             (Cockcroft/Gault formula); (4) Coagulation function: INR ≤ 1.5, APTT ≤ 1.5 ULN; (5)
             ALP ≤ 2.5 ULN, ALP ≤ 5 ULN. for bone metastasis subjects,

          -  tumor tissue samples that can meet the detection of PD-L1 expression can be provided
             during the screening period and within 4 weeks after selection.

          -  voluntarily sign informed consent form (ICF)

        Exclusion Criteria:

          -  before entering the group, the patients received any T cell co-stimulatory or immune
             checkpoint inhibitors, including, but not limited to, cytotoxic T lymphocyte
             associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors or other
             drugs targeting T cells; previously received anti-vascular endothelial growth factor
             (VEGF) or vascular endothelial growth factor receptor (VEGFR) therapy.

          -  active brain metastasis or meningeal metastasis.

          -  Patients with brain metastasis after treatment need to meet the following conditions:
             asymptomatic; no imaging evidence of progress ≥ 4 weeks after treatment; completion of
             treatment within 14 days before the first dose of the study drug; and no need to
             receive systemic corticosteroids (&gt; 10mg/ prednisone or equivalent) less than 14 days
             before the first dose of the study drug.

          -  radiotherapy for the chest and whole brain was completed less than 4 weeks before the
             first dose of the study drug (palliative radiotherapy for bone lesions is allowed ).

          -  the third space effusion with clinical symptoms, such as pericardial effusion, pleural
             effusion and peritoneal effusion which cannot be controlled by pumping or other
             treatment.

          -  active, known or suspected autoimmune diseases. Patients with vitiligo, type I
             diabetes, residual hypothyroidism caused by autoimmune thyroiditis that only require
             hormone replacement therapy, or are not expected to recur in the absence of external
             stimulation can be included in the group.

          -  corticosteroids (&gt; 10 mg/ prednisone or equivalent dose) or other immunosuppressants
             were used within 14 days before the first study.

        Inhalation or topical use of steroids and adrenal replacement steroids are allowed in the
        absence of active autoimmune disease; for patients receiving short-term, systemic
        immunosuppressive therapy, for example, glucocorticoids for nausea, vomiting, or allergic
        reaction management or preventive use can be admitted after consultation with the sponsor.
        Allow the use of salt corticosteroids in the treatment of postural hypotension and the use
        of low-dose glucocorticoid supplements in the treatment of adrenocortical insufficiency;

          -  subjects who had been vaccinated or planned to receive live vaccines within 4 weeks
             before the first study.

          -  Interstitial pneumonia (ILD) disease, drug-induced pneumonia, radiation pneumonia
             requiring steroid treatment or active pneumonia with clinical symptoms.

          -  active pulmonary tuberculosis or screening subjects with a history of active pulmonary
             tuberculosis infection within 1 year before treatment, whether treated or not.

          -  except for alopecia and fatigue, other toxicities caused by previous antineoplastic
             therapy need to be restored to CTCAE 5.0 ≤ 1 before the first dose. Some other
             toxicities caused by previous antineoplastic therapy are not expected to be resolved
             and have long-term persistent sequelae, such as neurotoxicity caused by platinum-based
             therapy, which are allowed to be included in the group.

          -  uncontrolled hypertension (systolic blood pressure ≥ 140mmHg and / or diastolic blood
             pressure ≥ 90 mmHg), history of hypertensive crisis or hypertensive encephalopathy.

          -  there are uncontrolled clinical symptoms or diseases of the heart, such as: (1)heart
             failure defined by New York Heart Association (NYHA)in grade 2 or above (2) unstable
             angina pectoris (3) myocardial infarction within 6 months (4) clinically significant
             supraventricular or ventricular arrhythmias need to be treated.

          -  uncontrolled active infections (e.g. need intravenous antibiotics, antifungal or
             antiviral therapy).

          -  HIV infection, HBsAg positive and peripheral blood HBV-DNA titer ≥ 0.5 × 10^3 copies /
             mL or HCV positive (HCV RNA or HCV Ab test indicated acute or chronic infection).

          -  pregnant or lactating women.

          -  known allergies to study drugs or excipients, and known severe allergic reactions to
             any monoclonal antibody; allergic history of carboplatin or etoposide.

          -  other malignant tumors occurred less than 5 years before the first dose, except for
             fully treatable cervical carcinoma in situ, basal cell or squamous cell skin cancer,
             local prostate cancer after radical resection, ductal carcinoma in situ after radical
             resection, and breast cancer without recurrence and metastasis after radical
             resection.

          -  known cases of mental illness, alcohol abuse, inability to quit smoking, drug use or
             substance abuse.

          -  have been treated with any other experimental drugs or participated in another
             interventional clinical study within 4 weeks before signing ICF
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Lu, doctor</last_name>
      <phone>+8621-62821990</phone>
      <email>shun_lu@hotmail.com</email>
    </contact>
    <contact_backup>
      <phone>＋8618017321552</phone>
      <email>drchenzhiwei@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ES-SCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

